159326-69-9

Usage

Uses

Used in Organic Synthesis:
1H-Pyrrole-2-carboxamide,1-amino-(9CI) serves as a key building block in organic synthesis, facilitating the construction of a wide range of organic compounds. Its presence in the synthesis process allows for the creation of complex molecular structures with potential applications in various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1H-Pyrrole-2-carboxamide,1-amino-(9CI) is utilized as a precursor in the development of new drug molecules. Its unique structure and reactivity make it a promising candidate for the design of innovative therapeutic agents, particularly those targeting specific biological pathways or receptors.
Used in Chemical Research:
1H-Pyrrole-2-carboxamide,1-amino-(9CI) is also employed as a valuable tool in chemical research, particularly in the study of heterocyclic compounds. Its distinctive properties provide insights into the reactivity and behavior of such compounds in chemical reactions, contributing to the advancement of chemical knowledge and the development of novel synthetic methodologies.
Used in Material Science:
1H-Pyrrole-2-carboxamide,1-amino-(9CI)'s unique structure and properties may also find applications in material science, where it could be used to develop new materials with specific properties, such as conductivity, stability, or reactivity, depending on the context of its incorporation into the material matrix.

InChI:InChI=1/C5H7N3O/c6-5(9)4-2-1-3-8(4)7/h1-3H,7H2,(H2,6,9)

Upstream product

• 159326-66-6 N-amino-1H-pyrrole-2-carbonitrile 
• 1003-29-8 2-pyrrole aldehyde 
• 4513-94-4 1H-pyrrole-2-carbonitrile 
• 159326-70-2 1-formylaminopyrrole-2-carboxamide 

Downstream Products

• 159326-70-2 1-formylaminopyrrole-2-carboxamide 
• 159326-73-5 1-<amino>pyrrole-2-carboxamide 
• 918538-04-2 pyrrolo[2,1-f][1,2,4]triazine-2,4(1H, 3H)-dione 
• 1204245-24-8 1-(2,2-difluoro-2-(4-fluorophenyl)acetamido)-1H-pyrrole-2-carboxamide 
• 918538-08-6 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine 
• 918538-05-3 2,4-dichloro-pyrrolo[2,1-f][1,2,4]triazine 
• 1001353-82-7 2,4-dichloropyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde 
• 1001353-78-1 (S)-1-(4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-2-methylpyrrolidine-2-carboxylic acid 

Relevant academic research and scientific papers

Substituted heteroaryl compounds and compositions and uses thereof

The invention provides a substituted heteroaryl compound and a composition thereof, and applications of the compound and the composition. The compound is a compound as shown in a formula I, or stereoisomer, tautomer, oxynitride, solvate, metabolite, pharmaceutically-acceptable salt or prodrug of the compound as shown in the formula I. The invention also provides a pharmaceutical composition containing the above-mentioned compound; and the above-mentioned compound and the pharmaceutical composition are capable of adjusting the activity of JAK kinases and are applied in prevention, treatment, therapy and alleviation of JAK kinase mediated diseases or disorders.

2 - amino-pyrrolo [1, 2 - f] [1, 2, 4] triazine compounds, synthetic method and application

The invention discloses 2-aminopyrrolo[1,2-f][1,2,4]triazine compounds, and a synthesis method and application thereof, particularly 2-aminopyrrolo[1,2-f][1,2,4]triazine compounds, or pharmaceutically acceptable salts, hydrate, solvate or prodrug thereof.

Synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound

The invention discloses a synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound. The compound belongs to a novel-structure compound. The synthesis method is high in operating safety, mild in reaction condition and suitable for industrial production. The activity and the selectivity of BTK kinase and the in-vitro proliferation activity of a leukemia cell line are test, it is verified that the compound has the selective and irreversible inhibition effect on the BTK kinase, and has the different-degree inhibition effect on leukemia cells. According to measurement, the compound also has the good anti-arthritic activity on a collagen-induced arthritis (rCIA) model. The pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound can be used for preparing medicine for treating arthritis and leukemia.

Heterocyclic amines Hedgehog signal pathway inhibitor

The invention relates to the field of biological medicine, in particular to a heterocyclic amine compound and an application thereof, namely a general formula (I) compound and acceptable salt in the pharmaceutical field. The compound can be used in the Hedgehog signal transduction inhibitor application and various medical applications (please see the formula in the specification). The invention further relates to a preparation method with the general formula (I).

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a JAK-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated disease.

Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors

A novel series of Hh signaling pathway inhibitors were designed by replacing the pyrimidine skeleton of our earlier reported lead compound 1 with pyrrolo[2,1-f][1,2,4]triazine scaffold. Starting from this new scaffold, SAR exploration was investigated based on structural modification on A-ring, C-ring and D-ring. And several much potent compounds were studies in vivo to profile their pharmacokinetic properties. Finally, optimization leads to the identification of compound 19a, a potent Hh signaling pathway inhibitor with superior potency in vitro and satisfactory pharmacokinetic properties in vivo.

JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are pyrrolotriazine compounds for treatment of JAK kinase, including JAK2 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

AURORA KINASE MODULATORS AND METHOD OF USE

The present invention relates to chemical compounds having a general formula (I) wherein A1-5 and 7-8, D', L1, L2, R1, R3, R6-8, n and o are defined herein, and synthetic intermediates, which are capable of modulating the activity of Aurora kinase proteins and, thereby, influencing various disease states and conditions related to the activities of Aurora kinases. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

HCV INHIBITING BI-CYCLIC PYRIMIDINES

The present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to processes for pre

Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template

The pyrrolo[2,1-f][1,2,4]triazine nucleus was identified as a novel kinase inhibitor template which effectively mimics the well-known quinazoline kinase inhibitor scaffold. Attachment of a 4-((3-chloro-4-fluorophenyl)amino) substituent to the template provided potent biochemical inhibitors of the tyrosine kinase activity of EGFR, as well as inhibition of cellular proliferation of the human colon tumor cell line DiFi. Attachment of a 4-((3-hydroxy-4-methylphenyl)amino) substituent provided potent inhibitors of VEGFR-2 which also showed effects on the VEGF-dependent proliferation of human umbilical vein endothelial cells. Biological activity was maintained with substitution at positions 5 or 6, but not 7, suggesting that the former positions are promising sites for introducing side chains which modulate physicochemical. properties. Preliminary inhibition studies with varying ATP concentrations suggest that, like the quinazoline-based kinase inhibitors, the pyrrolotriazine-based inhibitors bind in the ATP pocket.